Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles, letters, reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
"This journal fills an important need in providing reviews, covering the moving area of new cancer drug targets"
Paul Workman
CRC Centre for Cancer Therapeutics, England
Bentham Science is a science, technology, and medical (STM) publisher, providing academic researchers and industrial professionals with the latest information in diverse fields of science and technology. Our peer-reviewed scholarly journals and books have an ever-increasing readership of millions of researchers worldwide.
Bentham Science currently publishes more than 100 journals in both electronic and printed formats. Our journals cover various disciplines in pharmaceutical research and development, medical subspecialties, engineering, technology, and social sciences. The journals are indexed in recognized indexing agencies, such as Journal Citation Reports/Science Edition, MEDLINE/Index Medicus, PubMed, Scopus, Chemical Abstracts, EMBASE. ... Read More
